, Volume 67, Issue 12, pp 1800–1800 | Cite as

Bevacizumab in First-Line Treatment of Metastatic Breast Cancer

A Viewpoint by David Miles
  • David Miles
Adis Drug Profile Guest Commentary


Breast Cancer Vascular Endothelial Growth Factor Paclitaxel Bevacizumab Metastatic Breast Cancer 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Cobleigh MA, Langmuir VK, Sledge GW, et al. A phase I/II dose-escalation trial of bevacizumab in previously treated metastatic breast cancer. Sem Oncol 2003; 30 (5 Suppl. 16): 117–24CrossRefGoogle Scholar
  2. 2.
    Miller KD, Chap LI, Holmes FA, et al. Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol 2005; 23(4): 792–9PubMedCrossRefGoogle Scholar

Copyright information

© Adis Data Information BV 2007

Authors and Affiliations

  • David Miles
    • 1
  1. 1.Mount Vernon Cancer CentreNorthwoodEngland

Personalised recommendations